Phase II trial of PSA-IL2-GM-CSF-vaccine in patients with prostate cancer

Trial Profile

Phase II trial of PSA-IL2-GM-CSF-vaccine in patients with prostate cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2017 According to an OncBioMune Pharmaceuticals media release, the trial protocol of the study is now under review by the Regulatory Committee at Beth Israel Deaconess Medical Center/Harvard Medical School, the host hospital network for the study.
    • 13 Jul 2017 According to an OncBioMune Pharmaceuticals media release, the protocol is awaiting approval from the Institutional Review Board (IRB) at the host hospital, a preeminent North-eastern U.S. cancer research network. The protocol was previously submitted to the U.S. Food and Drug Administration and received no comments within the 30-day comment period.
    • 20 Jun 2017 According to an OncBioMune Pharmaceuticals media release, this study is expected to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top